<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946981</url>
  </required_header>
  <id_info>
    <org_study_id>AFCRO-128</org_study_id>
    <nct_id>NCT04946981</nct_id>
  </id_info>
  <brief_title>Recovery and Muscle Function After Supplementation With Turmeric</brief_title>
  <acronym>RECOFAST</acronym>
  <official_title>A Placebo Controlled, Randomised, Crossover Clinical Trial to Evaluate the Effect of Turmipure Gold® in Muscle Pain and Function Recovery in Moderately Active Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naturex SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atlantia Food Clinical Trials</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Naturex SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to test the capacity of a five-day supplementation of Turmipure&#xD;
      Gold® to improve exercise-induced muscle pain and function recovery in moderately active&#xD;
      adults after exercise-induced muscle damage&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on Perceived Muscle Soreness</measure>
    <time_frame>72 hours</time_frame>
    <description>Perceived Muscle Soreness in quadriceps during squatting activities assessed by VAS (0-100 mm, after two tries)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change on Muscle damage</measure>
    <time_frame>72 hours</time_frame>
    <description>Muscle damage assessed by circulating levels of Creatine kinase in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Isometric Muscle function recovery</measure>
    <time_frame>72 hours</time_frame>
    <description>Muscle function recovery assessed on quadriceps muscular function during isometric contractions recording the torque (Nm) using Biodex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Isokinetic Muscle function recovery</measure>
    <time_frame>72 hours</time_frame>
    <description>Muscle function recovery assessed on quadriceps muscular function during isokinetic extensions recording the torque (Nm) using Biodex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Muscle power recovery</measure>
    <time_frame>72 hours</time_frame>
    <description>Muscle power recovery assessed by Peak power (Watts) using vertical jump tests (best performance and average of 3 tries)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Muscle ROM recovery</measure>
    <time_frame>72 hours</time_frame>
    <description>Muscle ROM recovery assessed by Range Of Movement using a goniometer (knee flexion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Perceived wellness and well-being</measure>
    <time_frame>72 hours</time_frame>
    <description>Perceived wellness and well-being is assessed by a psychometric test evaluating fatigue, sleep quality, general muscle soreness, stress, and mood (0-25, 25 indicating best feelings of wellness and well-being)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on Perceived exertion during exercise</measure>
    <time_frame>30 min</time_frame>
    <description>Perceived exertion through breathing difficulty during exercise assessed by the Borg Rating of Perceived Exertion (0-10, 10 indicating maximal difficulty)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Muscle Soreness</condition>
  <condition>Pain</condition>
  <condition>Muscle Damage</condition>
  <arm_group>
    <arm_group_label>Randomized Crossover_Sequence 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants who meet the eligibility criteria will be randomized and will receive first the experimental product Turmipure GOLD® during the first study phase and then the placebo control during the second study phase. Both study phases are separated by a washout period of minimum 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Crossover_Sequence 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants who meet the eligibility criteria will be randomized and will receive first the placebo control during the first study phase and then the experimental product Turmipure GOLD® during the second study phase. Both study phases are separated by a washout period of minimum 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Turmipure Gold®</intervention_name>
    <description>TPG: Turmipure GOLD® - 1 capsule per day - as prescribed</description>
    <arm_group_label>Randomized Crossover_Sequence 1</arm_group_label>
    <arm_group_label>Randomized Crossover_Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: colored acacia gum - 1 capsule per day - as prescribed</description>
    <arm_group_label>Randomized Crossover_Sequence 1</arm_group_label>
    <arm_group_label>Randomized Crossover_Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy free-living males&#xD;
&#xD;
          -  Age: 25-45 years old&#xD;
&#xD;
          -  Have a BMI between 18.5 and 28 kg/m²&#xD;
&#xD;
          -  Moderately active with running 15-20 km per week&#xD;
&#xD;
          -  With 1 to 4h of training per week, with maximum 1h of lower body heavy-load or&#xD;
             resistance training (e.g., Hill running or hiking, HIT exercise, Squats, Lunges,&#xD;
             Leg-press, Bench steps, etc.)&#xD;
&#xD;
          -  Consent to the study protocol and to comply with study product&#xD;
&#xD;
          -  Willing to limit caffeine, smoking, and alcohol consumption during the entire study&#xD;
             period with no more than 5 cigarettes per day and 2 drinks. Also, alcohol consumption&#xD;
             will not be allowed 24hours prior to exercise-induced muscular damage&#xD;
&#xD;
          -  Willing to refrain from training for 3 days before the first test, 5 days before each&#xD;
             damage-inducing exercise and during each supplementation phase, including active&#xD;
             recovery exercises such as swimming, cycling at low intensity, unusual distance&#xD;
             walking (however such should be encouraged during the 14 days wash-out)&#xD;
&#xD;
          -  Willing to refrain the use of anti-inflammatory/pain reliever drugs such as&#xD;
             paracetamol, NSAIDs, etc., during each supplementation phase, from 24 hours prior to&#xD;
             72 hours following the exercise-induced muscular damage&#xD;
&#xD;
          -  Willing to refrain from 'recovery' treatments over the 72 hours following the damage&#xD;
             inducing exercise such as:&#xD;
&#xD;
               1. Hydrotherapy - cold water immersion, hot water immersion, or contrast therapy (as&#xD;
                  well as Jacuzzis, Steam baths, or Saunas)&#xD;
&#xD;
               2. Massage - self, foam rolling, etc.&#xD;
&#xD;
               3. Stretching&#xD;
&#xD;
               4. Compression garments&#xD;
&#xD;
               5. Topical applications - Tiger Balm, Deep Heat etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with any indicators of arthritis, joint disorders chronic pain syndrome,&#xD;
             muscle disorder diseases (e.g., fibromyalgia, etc.)&#xD;
&#xD;
          -  History of surgery or significant injury in joints or in the lower limb in the last&#xD;
             six months prior to study enrolment, or an anticipated need for surgical or invasive&#xD;
             procedure that will be performed during the study&#xD;
&#xD;
          -  Using omega-3-fatty acid, probiotic supplements, vitamins, minerals, or any dietary&#xD;
             supplements (including botanicals), especially to maintain joint health 4 weeks prior&#xD;
             to screening and during the entire study. Potential supplements include but are not&#xD;
             limited to Beta-alanine, Creatine, HMB, Carnosine, Taurine, androstenedione, DHEA,&#xD;
             Whey protein, or a pre-workout supplement&#xD;
&#xD;
          -  Following any specific diet such as high-protein, vegetarian, vegan, etc&#xD;
&#xD;
          -  Taking any drugs such as antibiotics, laxatives, or immunosuppressant drugs&#xD;
&#xD;
          -  History of glucocorticoid injection or hyaluronic acid injections within 3 months&#xD;
             prior to enrolment&#xD;
&#xD;
          -  Participants near or in the peak of training for an athletic race (half or marathon,&#xD;
             cycling tour or triathlon)&#xD;
&#xD;
          -  History or current significant cardiovascular, pulmonary, renal, liver, digestive&#xD;
             (including an inflammatory bowel disease), infectious disease, systemic disease,&#xD;
             immune disorder, or metabolic/endocrine disorders (including diabetes mellitus) or&#xD;
             other disease that would preclude supplement ingestion and/or assessment of study&#xD;
             objectives, including uncontrolled hypertension, uncontrolled thyroidism or lipidaemia&#xD;
             that is not on stable medication for at least 3 months.&#xD;
&#xD;
          -  Participant has any concurrent medical or psychiatric condition that, in the opinion&#xD;
             of the Investigator, would compromise his/her ability to comply with the study&#xD;
             requirements&#xD;
&#xD;
          -  Participant with history of drug and / or alcohol abuse at the time of enrolment&#xD;
&#xD;
          -  Any previous or current cancer diagnosis (including a benign or malign tumour of&#xD;
             intestine or colon)&#xD;
&#xD;
          -  Current illnesses which could interfere with the study (e.g., prolonged severe&#xD;
             diarrhoea, regurgitation/severe, difficulty swallowing)&#xD;
&#xD;
          -  Known allergy to components of the test product or sensitivity to herbal products or&#xD;
             with a medical history of food allergies&#xD;
&#xD;
          -  Participants taking any anticoagulant or heparin treatment (including aspirin)&#xD;
&#xD;
          -  Clinically significant abnormal laboratory results at screening&#xD;
&#xD;
          -  Participant currently involved in any other clinical trial or having participated in a&#xD;
             trial within 90 days prior to randomisation.&#xD;
&#xD;
          -  Any other condition which in the Investigator's opinion may adversely affect the&#xD;
             subject's ability to complete the study or its measures or which may pose significant&#xD;
             risk to the subject.&#xD;
&#xD;
          -  History of non-compliance with medical treatments or recommendations.&#xD;
&#xD;
          -  Participants who are required to perform squatting motions or descend a lot of stairs&#xD;
             in their daily work activities, which may be painful following the Exercise Induced&#xD;
             Muscle Damage.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Dinan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlantia Clinical Food Trials</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trevor Wood, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sport Physiologist University College Cork</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie Laval, PhD</last_name>
    <phone>+33 4 90 23 70 76</phone>
    <email>julie.laval@givaudan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pascale Fança-Berthon, PhD</last_name>
    <phone>+33 4 90 23 28 40</phone>
    <email>pascale.fanca-berthon@givaudan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Atlantia Food Clinical Trials</name>
      <address>
        <city>Cork</city>
        <zip>T23 R50R</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Goodbody</last_name>
      <phone>+353 21 430 7442</phone>
      <email>egoodbody@atlantiafoodtrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Kerin</last_name>
      <phone>+353 21 430 7442</phone>
      <email>rkerin@atlantiafoodtrials.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Turmeric</keyword>
  <keyword>Curcuminoids</keyword>
  <keyword>Sport performance &amp; recovery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

